In 12 chronic bronchitic out-patients, during 3 successive days, the variations of FEV1 and Vmax25 were studied at 15, 30, 45,60, 120, and 180min after inhalation of: (1) [0.1 mg fenoterol (F) associated with 0.04 mg ipratropium bromide (IB)]; (2) [0.2 mg salbutamol (S)], and (3) [0.5 mg terbutaline (T)]. There were no secondary effects resulting from any treatment. Maximum effectiveness appeared on FEV1 at 60 min with F + IB, and at 45 min with S and T. On Vmax25, it was produced after 30 min with F + IB and no modifications in this parameter were observed either with S or with T. After 15 min, there were changes on FEV1 with the three products: P < 0.001 for F+ IB and S; p < 0.01 for T. The variation persisted for up to 120 min with F + IB (p < 0.001) and with S (p < 0.05), and for up to 60 min with T(p < 0.01). With F+ IB, Vmax25 increased since after 15 min (p < 0.001) and up to 60 min (p < 0.01). In conclusion, the association of a small dose of F to IB provides as positive results as S, and better than T, in a group of chronic bronchitic out-patients.

Keywords:
Bronchodilators, Ipratropium, β-Mimetics, Chronic bronchitics
This content is only available via PDF.
© 1986 S. Karger AG, Basel
1986
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.